Wealth Alliance Advisory Group LLC acquired a new position in shares of Haemonetics Co. (NYSE:HAE) during the 3rd quarter, Holdings Channel reports. The institutional investor acquired 2,000 shares of the medical instruments supplier’s stock, valued at approximately $229,000.
A number of other hedge funds and other institutional investors have also recently bought and sold shares of HAE. Wagner Bowman Management Corp purchased a new position in shares of Haemonetics during the 2nd quarter valued at $224,000. Arjuna Capital purchased a new position in shares of Haemonetics during the 2nd quarter valued at $224,000. Granahan Investment Management Inc. MA purchased a new position in shares of Haemonetics during the 2nd quarter valued at $229,000. Welch & Forbes LLC purchased a new position in shares of Haemonetics during the 3rd quarter valued at $229,000. Finally, Oakbrook Investments LLC purchased a new position in shares of Haemonetics during the 3rd quarter valued at $229,000. Hedge funds and other institutional investors own 95.38% of the company’s stock.
HAE has been the topic of several research analyst reports. Zacks Investment Research upgraded shares of Haemonetics from a “hold” rating to a “strong-buy” rating and set a $122.00 price target on the stock in a report on Friday, October 12th. Barrington Research restated a “buy” rating and set a $127.00 price target on shares of Haemonetics in a report on Friday, October 5th. Morgan Stanley upped their price objective on shares of Haemonetics from $100.00 to $120.00 and gave the stock an “overweight” rating in a report on Wednesday, August 8th. Jefferies Financial Group reiterated a “buy” rating and issued a $125.00 price objective on shares of Haemonetics in a report on Tuesday, August 7th. Finally, TheStreet cut shares of Haemonetics from a “b” rating to a “c+” rating in a report on Monday, August 20th. Two research analysts have rated the stock with a hold rating, four have assigned a buy rating and two have issued a strong buy rating to the stock. The company has a consensus rating of “Buy” and a consensus price target of $102.67.
Haemonetics (NYSE:HAE) last issued its quarterly earnings data on Tuesday, August 7th. The medical instruments supplier reported $0.59 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.42 by $0.17. The firm had revenue of $229.35 million during the quarter, compared to analysts’ expectations of $219.52 million. Haemonetics had a net margin of 2.45% and a return on equity of 15.00%. On average, sell-side analysts forecast that Haemonetics Co. will post 2.28 earnings per share for the current fiscal year.
In other Haemonetics news, CFO William P. Mr. Burke sold 841 shares of the business’s stock in a transaction on Thursday, October 25th. The shares were sold at an average price of $46.76, for a total transaction of $39,325.16. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Pedro P. Granadillo sold 30,824 shares of the business’s stock in a transaction on Monday, September 17th. The stock was sold at an average price of $111.83, for a total transaction of $3,447,047.92. The disclosure for this sale can be found here. Insiders sold 37,173 shares of company stock valued at $4,059,457 over the last quarter. 1.04% of the stock is currently owned by corporate insiders.
Haemonetics Corporation, a healthcare company, provides hematology products and solutions. The company operates through five segments: North America Plasma; Americas Blood Center and Hospital; Europe, Middle East and Africa; Asia Pacific; and Japan. It offers automated plasma collection devices and related disposables, including NexSys PCS plasmapheresis system and PCS2 equipment and disposables, plasma collection containers, and intravenous solutions, as well as information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system.
Recommended Story: Float
Want to see what other hedge funds are holding HAE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Haemonetics Co. (NYSE:HAE).
Receive News & Ratings for Haemonetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Haemonetics and related companies with MarketBeat.com's FREE daily email newsletter.